Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Calls For Reform of England’s Unused Innovative Medicines Fund

Executive Summary

The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.

You may also be interested in...

England’s Unused Innovative Medicines Fund Under Fire Again

A group of UK academics have broadly welcomed the fund that will pay for innovative non-cancer drugs, but have expressed concern over issues such as the entry criteria and the definition of “high unmet need.” They also say safeguards are needed against possible financial loss to the National Health Service.

Ipsen Accuses Government Of Backward Step With Proposed Changes to Statutory Pricing Scheme

Ipsen and other experts have criticized proposals from the UK government on changes to the statutory scheme for the pricing of branded medicines. Plans for differential rebates are seen as too complex, meaning their impact is difficult to predict and they could end up costing the government more.

UK Government And Industry Still Far Apart In Talks on New Pricing Scheme

The UK pharmaceutical industry association, the ABPI, says it and the government are still far from reaching a deal on a new voluntary pricing agreement and has suggested that a transition to the statutory scheme could be on the cards if an acceptable deal cannot be secured.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts